The old article's list of 20 compounded-semaglutide states no longer describes the current program and should not be used to predict eligibility in 2026
Human GLP-1 based GLP-1RA includes liraglutide, albiglutide, dulaglutide, efpeglenatide, and semaglutide
However, more rigorous, controlled studies are necessary to determine whether GLP-1 medications are truly responsible
Exenatide has been shown to mitigate the phosphorylation of insulin receptor substrates and the accumulation of monomeric -synuclein
Age, genetics, baseline facial volume, skin elasticity, smoking history, sun damage, nutrition, and the degree of muscle loss all influence how visible the change becomes
A reputable program should be honest about compounded medications, use licensed pharmacy partners, avoid exaggerated claims, and never guarantee weight-loss results